Montelukast Junior Ratiopharm (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Junior Ratiopharm, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance treatment of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchospasm in pediatric patients. GNH USA supplies Montelukast Junior Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Junior Ratiopharm is a leukotriene‑targeting medication used in several respiratory and allergic conditions.

- Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchospasm: prevents airway narrowing triggered by physical activity.

Montelukast Junior Ratiopharm may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate discomfort. - Abdominal pain: intermittent stomach discomfort. - Cough: occasional dry cough. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests.

Before prescribing Montelukast Junior Ratiopharm, clinicians should consider several safety aspects.

- Assess asthma control before initiating: ensure the patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric events: watch for agitation, depression, or suicidal ideation. - Avoid use in patients with known hypersensitivity to montelukast or excipients. - Use with caution in hepatic impairment: dose adjustment may be required. - Store at room temperature: keep in the original container, protect from moisture and heat.

Montelukast Junior Ratiopharm can interact with several medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast efficacy. - Carbamazepine: may lower plasma levels of montelukast.

Moderate Interactions (Monitor Closely): - Warfarin: may alter INR; monitor coagulation parameters. - Theophylline: monitor for changes in bronchospasm control.